

	CD45 <sup>+</sup> / CD11b <sup>+</sup> cells (%)		CD45 <sup>+</sup> / CD11b <sup>-</sup> cells (%)	
	BSA-PBS group	tPA group	BSA-PBS group	tPA group
CD184 <sup>+</sup> / VEGFR-1 <sup>+</sup>	49.53 ± 1.91	72.09 ± 0.45*	50.48 ± 1.91	27.91 ± 0.45
CD184 <sup>+</sup>	32.67 ± 0.09	57.58 ± 1.62*	67.34 ± 0.09	42.42 ± 1.62
VEGFR-1 <sup>+</sup>	24.99 ± 1.82	43.04 ± 0.49*	75.01 ± 1.82	56.96 ± 0.49
c-Kit <sup>+</sup>	63.63 ± 3.15	76.93 ± 1.03*	36.37 ± 3.12	23.07 ± 1.03
c-Kit <sup>+</sup> / VEGFR-1 <sup>+</sup>	81.68 ± 3.59	94.32 ± 2.84*	18.32 ± 3.59	5.68 ± 2.84

PB mononuclear cells (PBMCs), isolated from tPA-treated or control C57BL/6 mice, were stained with antibodies against CD45, CD11b, VEGFR-1, CD184 (CXCR4) and c-Kit and analyzed by FACS on day 2 (n = 3; P < 0.05). The frequency of CD11b subpopulations coexpressing VEGFR-1, CD184 (CXCR-4) or c-Kit was determined.